Pioglitazone use and the risk of bladder cancer

This study aimed to identify the risk association between pioglitazone and bladder cancer. A nested case-control study was performed using a representative base randomly sampled from National Health Insurance enrollees. The source cohort of newly diagnosed diabetic patients from 1997 to 2009. Cases were identified as those diagnosis of bladder cancer from 2002 to 2009. For each case, four matched control were randomly selected. A multiple logistic regression model was used to estimate the tive magnitude of risk in relation to the use of pioglitazone. In total, 259 cases and 1036 trols were identified. The prevalent use of pioglitazone is similar in cases and (adjusted odds ratio, 1.20; 95% confidence interval, 0.58-2.49). Compared to nonusers, values were 1.08 (0.41-2.88) for those with cumulative pioglitazone use <= 8268 mg and (0.48-3.79) for those with cumulative pioglitazone use > 8268 mg. This study does not support for the risk association between pioglitazone exposure and bladder cancer. confirmation is needed due to the limitation of small case number with relatively exposure duration and lower cumulative dose. Copyright (C) 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All reserved.